Institution
University of Ioannina
Education•Ioannina, Greece•
About: University of Ioannina is a education organization based out in Ioannina, Greece. It is known for research contribution in the topics: Population & Large Hadron Collider. The organization has 7654 authors who have published 20594 publications receiving 671560 citations. The organization is also known as: Panepistimio Ioanninon.
Papers published on a yearly basis
Papers
More filters
••
Max Planck Society1, Free University of Berlin2, University of Colorado Boulder3, University of Ioannina4, Royal Berkshire NHS Foundation Trust5, University of Oxford6, Harvard University7, Mayo Clinic8, University of Miami9, University of Tübingen10, German Center for Neurodegenerative Diseases11, Boston University12, Emory University13, University of British Columbia14, Indiana University15, Wadsworth Center16, University College London17, VU University Amsterdam18, University of Lübeck19, University of Chicago20, Centre national de la recherche scientifique21, University of Toulouse22, National Institutes of Health23, Kobe University24, deCODE genetics25, University of Washington26, University of Münster27, Centers for Disease Control and Prevention28, University of Mainz29
TL;DR: This study provides an exhaustive and up-to-date summary of the status of PD genetics research that can be readily scaled to include the results of future large-scale genetics projects, including next-generation sequencing studies.
Abstract: More than 800 published genetic association studies have implicated dozens of potential risk loci in Parkinson’s disease (PD). To facilitate the interpretation of these findings, we have created a dedicated online resource, PDGene, that comprehensively collects and meta-analyzes all published studies in the field. A systematic literature screen of ,27,000 articles yielded 828 eligible articles from which relevant data were extracted. In addition, individual-level data from three publicly available genome-wide association studies (GWAS) were obtained and subjected to genotype imputation and analysis. Overall, we performed meta-analyses on more than seven million polymorphisms originating either from GWAS datasets and/or from smaller scale PD association studies. Metaanalyses on 147 SNPs were supplemented by unpublished GWAS data from up to 16,452 PD cases and 48,810 controls. Eleven loci showed genome-wide significant (P,5610 28 ) association with disease risk: BST1, CCDC62/HIP1R, DGKQ/GAK, GBA, LRRK2, MAPT, MCCC1/LAMP3 ,P ARK16,SNCA, STK39 ,a ndSYT11/RAB25. In addition, we identified novel evidence for genome-wide significant association with a polymorphism in ITGA8 (rs7077361, OR 0.88, P=1.3610 28 ). All meta-analysis results are freely available on a dedicated online database (www.pdgene.org), which is cross-linked with a customized track on the UCSC Genome Browser. Our study provides an exhaustive and up-to-date summary of the status of PD genetics research that can be readily scaled to include the results of future large-scale genetics projects, including next-generation sequencing studies.
537 citations
••
TL;DR: Current standards for safety reporting in randomized trials should be revised to address this inadequacy, as generalizable data on drug safety reporting are sparse and largely inadequate.
Abstract: ContextRandomized trials with adequate sample size offer an opportunity to
assess the safety of new medications in a controlled setting; however, generalizable
data on drug safety reporting are sparse.ObjectiveTo scrutinize the completeness of safety reporting in randomized trials.Design, Setting, and PatientsSurvey of safety reporting in 192 randomized drug trials 7 diverse topics
with sample sizes of at least 100 patients and at least 50 patients in a study
arm (N = 130074 patients). Trial reports were identified from comprehensive
meta-analyses in 7 medical areas.Main Outcome MeasuresAdequate reporting of specific adverse effects and frequency and reasons
for withdrawals due to toxic effects; article space allocated to safety reporting
and predictors of such reporting.ResultsSeverity of clinical adverse effects and laboratory-determined toxicity
was adequately defined in only 39% and 29% of trial reports, respectively.
Only 46% of trials stated the frequency of specific reasons for discontinuation
of study treatment due to toxicity. For these 3 parameters, there was significant
heterogeneity in rates of adequate reporting across topics (P = .003, P<.001, and P = .02, respectively). Overall, the median space allocated to safety
results was 0.3 page. A similar amount of space was devoted to contributor
names and affiliations (P = .16). On average, the
percentage of space devoted to safety in the results section was 9.3% larger
in trials involving dose comparisons than in those that did not (P<.001) and 3.8% smaller in trials reporting statistically significant
results for efficacy outcomes (P = .047).ConclusionsThe quality and quantity of safety reporting vary across medical areas,
study designs, and settings but they are largely inadequate. Current standards
for safety reporting in randomized trials should be revised to address this
inadequacy.
533 citations
••
University of Ioannina1, International Agency for Research on Cancer2, University of Ottawa3, Erasmus University Rotterdam4, Imperial College London5, University of California, Berkeley6, Albert Einstein College of Medicine7, Emory University8, University of Cambridge9, Wellcome Trust Centre for Human Genetics10, University of Oxford11, University of Alabama at Birmingham12, University of Pennsylvania13, National Institutes of Health14, Centers for Disease Control and Prevention15
TL;DR: A proposed semi-quantitative index assigns three levels for the amount of evidence, extent of replication, and protection from bias, and also generates a composite assessment of 'strong', 'moderate' or 'weak' epidemiological credibility.
Abstract: Established guidelines for causal inference in epidemiological studies may be inappropriate for genetic associations. A consensus process was used to develop guidance criteria for assessing cumulative epidemiologic evidence in genetic associations. A proposed semi-quantitative index assigns three levels for the amount of evidence, extent of replication, and protection from bias, and also generates a composite assessment of 'strong', 'moderate' or 'weak' epidemiological credibility. In addition, we discuss how additional input and guidance can be derived from biological data. Future empirical research and consensus development are needed to develop an integrated model for combining epidemiological and biological evidence in the rapidly evolving field of investigation of genetic factors.
533 citations
••
U. Bhawandeep1, Vardan Khachatryan, Albert M. Sirunyan, Armen Tumasyan +2289 more•Institutions (147)
TL;DR: In this paper, the trigger system consists of two levels designed to select events of potential physics interest from a GHz (MHz) interaction rate of proton-proton (heavy ion) collisions.
Abstract: This paper describes the CMS trigger system and its performance during Run 1 of the LHC. The trigger system consists of two levels designed to select events of potential physics interest from a GHz (MHz) interaction rate of proton-proton (heavy ion) collisions. The first level of the trigger is implemented in hardware, and selects events containing detector signals consistent with an electron, photon, muon, tau lepton, jet, or missing transverse energy. A programmable menu of up to 128 object-based algorithms is used to select events for subsequent processing. The trigger thresholds are adjusted to the LHC instantaneous luminosity during data taking in order to restrict the output rate to 100 kHz, the upper limit imposed by the CMS readout electronics. The second level, implemented in software, further refines the purity of the output stream, selecting an average rate of 400 Hz for offline event storage. The objectives, strategy and performance of the trigger system during the LHC Run 1 are described.
532 citations
••
TL;DR: A test to explore biases stemming from the pursuit of nominal statistical significance was developed and demonstrated a clear or possible excess of significant studies in 6 of 8 large meta-analyses and in the wide domain of neuroleptic treatments.
Abstract: Background The published clinical research literature may be distorted by the pursuit of statistically significant results.Purpose We aimed to develop a test to explore biases stemming from the pur...
529 citations
Authors
Showing all 7724 results
Name | H-index | Papers | Citations |
---|---|---|---|
John P. A. Ioannidis | 185 | 1311 | 193612 |
Kay-Tee Khaw | 174 | 1389 | 138782 |
Elio Riboli | 158 | 1136 | 110499 |
Mercouri G. Kanatzidis | 152 | 1854 | 113022 |
Dimitrios Trichopoulos | 135 | 818 | 84992 |
Gyorgy Vesztergombi | 133 | 1444 | 94821 |
Niki Saoulidou | 132 | 1065 | 81154 |
Apostolos Panagiotou | 132 | 1370 | 88647 |
Ioannis Evangelou | 131 | 1225 | 82178 |
Ioannis Papadopoulos | 129 | 1201 | 85576 |
Nikolaos Manthos | 129 | 1256 | 81865 |
Panagiotis Kokkas | 128 | 1234 | 81051 |
Costas Foudas | 128 | 1112 | 83048 |
Zoltan Szillasi | 128 | 1214 | 84392 |
Matthias Schröder | 126 | 1421 | 82990 |